Reading ZTS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZTS free→
Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-16
Intact
$79.31-0.80%
Close 2026-06-16 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is mixed, and risk is elevated, while the sector backdrop is a headwind. Peer multiples imply a price roughly in line with where it trades (about fair); the read is fair. If ZTS cuts guidance on the next call, that's a meaningful negative. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $33.36B
- Employees
- —
- IPO date
- 2012-08-13
- Next earnings
- 2026-08-04
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 8 valuation methods, at three horizons. Current price $79.31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfull
$76.90consensus
Range $64.85 – $81.59
vs price: +3% above
Method agreement — · 8 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$112.55consensus
Range $97.98 – $122.09
vs price: -30% below
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Aligned with peersmedium confidence
At $80 ZTS trades at 13× p/e, in line with its 13× p/e peer median. Our $79 fair value reflects that, medium confidence. Analysts: $95–$160. Not investment advice.
Multiple (P/E)
12.9x
peer 12.9x · own history 31.0x
Premium
1.0x peer
0.4x its own history
Growth the price needs
2%
our forecast 11%
Our fair value
$78.68
range $65.91 – $82.31
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fullfair12-month view
What's priced inJustified
The market is pricing in roughly 2% near-term growth, in line with our forecast of about 11%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
87th pctl · Health Care
Earnings quality
fragileOver the trailing year it converted 1.04x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
30th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
volatileEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Bearish13 analysts, 55% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $1.90 → $1.86 (-2.0% / 30d). 2 raised, 9 cut, 13 covering analysts.
Rating actions
0 upgrades, 1 downgrade / 30d, 2 maintained. 55% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 18.7% above current price.
Material events
0 positive, 0 negative / 30d.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- neutral
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$117.
How much price usually moves either way.
On a bad day, this stock has moved -$287.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,415.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · valuation_labelsmall change
Valuation label changed from 'fair' to 'full'.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceMonthsactive 22d
Watch for EPS guidance update for 2026
Why it matters: EPS guidance will indicate how profit expectations are changing. This affects how investors view the company's future.
What confirms / what disproves
Confirms:Management expects higher EPS for 2026. This is above current forecasts.
Disproves:Management lowers EPS guidance for 2026 or keeps it unchanged.
Management priorities
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-124d agoYahoo! Finance
Difficult Q1 update raises concerns about future guidance.
ChallengesUnconfirmed report
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like TEVA, HLN, and UTHR keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting ZTS and other Healthcare names. Worth watching these names for early signals.
- If ZTS raises forward guidance on the next earnings call (currently NEW as of 2026-05-07), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If ZTS cuts guidance on the next call (currently NEW as of 2026-05-07), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like TEVA, HLN, and UTHR start missing or guiding lower, the Healthcare tailwind helping ZTS and other Healthcare names could fade. Watch these names for early warning.
- If ZTS misses again next quarter like this past one (a miss of -8% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-2226d agoItem 5.02
of this Current Report on Form 8-K, on May 20, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company’s shareholders voted on five proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2026 (the “Proxy Statement”). There were 379,034,516 shares of common stock present at the Annual Meeting in person or by proxy, which represented 90.13% of the voting power of the sha…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
About the same as last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.